196 related articles for article (PubMed ID: 38072965)
1. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
2. Single Protein Encapsulated SN38 for Tumor-Targeting Treatment.
Yu CJ; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
Res Sq; 2023 Jul; ():. PubMed ID: 37546894
[TBL] [Abstract][Full Text] [Related]
3. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
4. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
5. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X
J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543
[TBL] [Abstract][Full Text] [Related]
6. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment.
Zhang R; Luo Y; Du C; Wu L; Wang Y; Chen Y; Li S; Jiang X; Xie Y
Bioorg Med Chem Lett; 2023 Feb; 81():129128. PubMed ID: 36639036
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor activity of a nanoparticulate SN38.
Al-Kasspooles MF; Williamson SK; Henry D; Howell J; Niu F; Decedue CJ; Roby KF
Invest New Drugs; 2013 Aug; 31(4):871-80. PubMed ID: 23299391
[TBL] [Abstract][Full Text] [Related]
10. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
12. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
[No Abstract] [Full Text] [Related]
15. Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Wu C; Zhang Y; Yang D; Zhang J; Ma J; Cheng D; Chen J; Deng L
Int J Nanomedicine; 2019; 14():75-85. PubMed ID: 30587986
[TBL] [Abstract][Full Text] [Related]
16. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Evaluation of Glucose Transporter Inhibitor-SN38 Conjugates for Targeting Colorectal Cancer.
Chiu PF; Chang CK; Huang PS; Lin YY; Lin CS; Yang HY; Hsu LC; Yu LC; Liang PH
J Med Chem; 2023 Jul; 66(14):9684-9696. PubMed ID: 37413981
[TBL] [Abstract][Full Text] [Related]
18. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
[TBL] [Abstract][Full Text] [Related]
19. Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Sepehri N; Rouhani H; Ghanbarpour AR; Gharghabi M; Tavassolian F; Amini M; Ostad SN; Ghahremani MH; Dinarvand R
Biomed Res Int; 2014; 2014():963507. PubMed ID: 24895635
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]